Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Barath Chari is a partner in Wilson Sonsini’s San Francisco office. Barath represents technology companies at all stages of growth, from bootstrapped start-ups to leading global enterprises, in complex business transactions involving technology and intellectual property. He also has deep experience in assisting technology companies and their investors with mergers, acquisitions, divestitures, and financing matters. A Washington, D.C., transplant resident in the firm’s San Francisco office, Barath understands how the federal government transacts with technology companies, and helps technology companies sell products to federal government customers and collaborate with the federal government on research and development. He also leverages his pre-law experience as a software engineer to provide informed legal advice on technical topics such as open source software.
Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.
Dr. Norm Hovijitra is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. He advises emerging and established companies in the life sciences industry on legal and business issues associated with the development, manufacture, and commercialization of their products and technologies, including matters relating to intellectual property strategy and patents.